文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FMISO缺氧显像在人肿瘤异种移植模型中证实艾日布林消除肿瘤缺氧

Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models.
PubMed 文献 · EJNMMI Res · 2019-06-03

本研究在携带人肿瘤异种移植瘤的小鼠中,于腹腔注射单剂艾日布林(0.3或1.0 mg/kg)或生理盐水3天后,用18F-FMISO PET与免疫组化缺氧标志物哌莫硝唑评估肿瘤缺氧状态。结果显示艾日布林治疗后肿瘤18F-FMISO摄取与哌莫硝唑阳性缺氧面积显著降低,而微血管数增加,PET/CT证实18F-FMISO分布减少。提示18F-FMISO PET可能用于检测艾日布林治疗的早期反应。

要点

  • 艾日布林治疗后肿瘤18F-FMISO摄取与哌莫硝唑阳性缺氧面积显著降低。
  • 艾日布林治疗同时使肿瘤微血管数增加。
  • 18F-FMISO PET可能用于检测艾日布林治疗的早期反应。

核心结论

  • 18F-FMISO显像证实艾日布林治疗可消除肿瘤缺氧状态,并伴随微血管密度增加。
  • 18F-FMISO PET可能为临床接受艾日布林治疗患者的早期疗效检测提供可能。

研究设计与样本

  • 研究采用携带人癌细胞异种移植瘤的小鼠模型。
  • 小鼠腹腔注射单剂艾日布林(0.3或1.0 mg/kg)或生理盐水,3天后注射18F-FMISO与哌莫硝唑并评估肿瘤内18F-FMISO积聚与组织学特征。
  • 另在艾日布林(0.3 mg/kg,腹腔注射)治疗前后进行PET/CT。

主要发现

  • 艾日布林治疗组肿瘤的18F-FMISO积聚水平与哌莫硝唑阳性缺氧面积百分比显著降低。
  • 艾日布林治疗组肿瘤微血管数更高。
  • PET/CT证实艾日布林治疗后肿瘤内18F-FMISO分布减少。

临床怎么用

  • 18F-FMISO PET有望用于临床接受艾日布林治疗患者的早期治疗反应检测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Eribulin, an inhibitor of microtubule dynamics, shows antitumor potency against a variety of solid cancers through its antivascular activity and remodeling of tumor vasculature. 18F-Fluoromisonidazole (18F-FMISO) is the most widely used PET probe for imaging tumor hypoxia. In this study, we utilized 18F-FMISO to clarify the effects of eribulin on the tumor hypoxic condition in comparison with histological findings. MATERIAL AND METHODS: Mice bearing a human cancer cell xenograft were intraperitoneally administered a single dose of eribulin (0.3 or 1.0 mg/kg) or saline. Three days after the treatment, mice were injected with 18F-FMISO and pimonidazole (hypoxia marker for immunohistochemistry), and intertumoral 18F-FMISO accumulation levels and histological characteristics were determined. PET/CT was performed pre- and post-treatment with eribulin (0.3 mg/kg, i.p.). RESULTS: The 18F-FMISO accumulation levels and percent pimonidazole-positive hypoxic area were significantly lower, whereas the number of microvessels was higher in the tumors treated with eribulin. The PET/CT confirmed that 18F-FMISO distribution in the tumor was decreased after the eribulin treatment. CONCLUSIONS: Using 18F-FMISO, we demonstrated the elimination of the tumor hypoxic condition by eribulin treatment, concomitantly with the increase in microvessel density. These findings indicate that PET imaging using 18F-FMISO may provide the possibility to detect the early treatment response in clinical patients undergoing eribulin treatment.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Zhao S, Yu W, Ukon N, et al. Elimination of tumor hypoxia by eribulin demonstrated by 18F-FMISO hypoxia imaging in human tumor xenograft models. EJNMMI Res. 2019. PMID: 31161539. doi:10.1186/s13550-019-0521-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。